Comparative effectiveness of vedolizumab and ustekinumab as induction therapy in anti-TNF refractory Crohn's disease: a multi-centre retrospective cohort study

被引：2
|
作者：
Townsend, T. [1 ]
Razanskaite, V. [2 ]
Michail, S. [1 ]
Morgan, J. [1 ]
Davies, M. [1 ]
Storey, D. [1 ]
Watters, C. [3 ]
Penman, D. [3 ]
Swaminathan, M. [4 ]
Sabine, J. [3 ]
Chapman, A. [2 ]
Vyas, A. [2 ]
Reilly, I. [4 ]
Flanagan, P. [3 ]
Bodger, K. [2 ]
Subramanian, S. [1 ]
机构：
[1] Royal Liverpool Univ Hosp, Gastroenterol, Liverpool, Merseyside, England
[2] Aintree Univ Hosp NHS Fdn Trust, Gastroenterol, Liverpool, Merseyside, England
[3] Arrowe Pk Hosp, Gastroenterol, Upton, England
[4] Countess Chester Hosp, Gastroenterol, Chester, Cheshire, England
来源：
JOURNAL OF CROHNS & COLITIS | 2019年 / 13卷
关键词：
D O I：
10.1093/ecco-jcc/jjy222.710
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P586
引用
收藏
页码：S407 / S408
页数：2
相关论文
共 50 条
  • [21] Efficacy of ustekinumab, vedolizumab, or a second anti-TNF agent after the failure of a first anti-TNF agent in patients with Crohn's disease: a multicentre retrospective study
    Cassandra, Rayer
    Nachury, Maria
    Arnaud, Bourreille
    Xavier, Roblin
    Laurent, Peyrin-Biroulet
    Stephanie, Viennot
    Mathurin, Flamant
    David, Laharie
    Benedicte, Caron
    Marie, Dewitte
    Laurent, Siproudhis
    Mathurin, Fumery
    Guillaume, Bouguen
    BMC GASTROENTEROLOGY, 2022, 22 (01)
  • [22] Ustekinumab Efficacy and Safety in Crohn's Disease Patients Refractory to Conventional and Anti-TNF Therapy: A Multicenter Retrospective Experience
    Wils, Pauline
    Bouhnik, Yoram
    Flourie, Bernard
    Brixi, Hedia
    Cosnes, Jacques
    Allez, Matthieu
    Bernard, Duclos
    Michetti, Pierre F.
    Grimaud, Jean-charles
    Bommelaer, Gilles
    Amiot, Aurelien
    Fumery, Mathurin
    Jerome, Filippi
    Abitbol, Vered
    Coffin, Benoit
    Simon, Marion
    Laharie, David
    Pariente, Benjamin
    GASTROENTEROLOGY, 2015, 148 (04) : S115 - S116
  • [23] COMPARISON OF SHORT AND LONG-TERM EFFICACY BETWEEN USTEKINUMAB AND VEDOLIZUMAB IN PATIENTS WITH CROHN'S DISEASE REFRACTORY TO ANTI-TNF THERAPY
    Manlay, Luc
    Boschetti, Gilles
    Pereira, Bruno
    Buisson, Anthony
    Nancey, Stephane
    GASTROENTEROLOGY, 2021, 160 (06) : S6 - S6
  • [24] Single Center Experience With Long-term Ustekinumab in Patients With Refractory Crohn's Disease (Prior Anti-TNF and Vedolizumab Therapy)
    Bennett, Audrey L.
    Evers, Lauren
    Duley, Caroline V.
    Annis, Kim
    Beaulieu, Dawn B.
    Adams, Dawn W.
    Schwartz, David A.
    Horst, Sara N.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2017, 112 : S397 - S398
  • [25] Accelerated dosing schedule with ustekinumab in anti-TNF refractory Crohn's disease
    Gonzalez, H. Aleman
    Stamp, K.
    Whitehead, E.
    Pattinson, A.
    Turnbull, J.
    Myers, S.
    Talbot, A.
    Sebastian, S.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I374 - I375
  • [26] ACCELERATED DOSING SCHEDULE WITH USTEKINUMAB IN ANTI-TNF REFRACTORY CROHN'S DISEASE
    Gonzalez, Haidee Aleman
    Stamp, Katie
    Whitehead, Emma
    Myers, Sally
    Turnbull, Jack
    Pattinson, Alison
    Talbot, Alison
    Sebastian, Shaji
    GUT, 2021, 70 : A98 - A98
  • [27] Accelerated dosing schedule with ustekinumab in anti-TNF refractory Crohn's disease
    Gonzalez, H. Aleman
    Stamp, K.
    Whitehead, E.
    Pattinson, A.
    Turnbull, J.
    Myers, S.
    Talbot, A.
    Sebastian, S.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I374 - I375
  • [28] Comparison of Short- and Long-Term Effectiveness between Anti-TNF and Ustekinumab after Vedolizumab Failure as First-Line Therapy in Crohn's Disease: A Multi-Center Retrospective Cohort Study
    Albshesh, Ahmad
    Bannon, Lian
    Sharar Fischler, Tali
    Truyens, Marie
    Vavricka, Stephan R. R.
    Tepes, Katja
    Pugliese, Daniela
    Savarino, Edoardo V. V.
    Zittan, Eran
    Drobne, David
    Roblin, Xavier
    Bar-Gil Shitrit, Ariella
    Armuzzi, Alessandro
    Lobaton, Triana
    Maharshak, Nitsan
    Yanai, Henit
    Ben-Horin, Shomron
    Kopylov, Uri
    JOURNAL OF CLINICAL MEDICINE, 2023, 12 (07)
  • [29] Correction: Efficacy of ustekinumab, vedolizumab, or a second anti-TNF agent after the failure of a first anti-TNF agent in patients with Crohn’s disease: a multicentre retrospective study
    Cassandra Rayer
    Maria Nachury
    Arnaud Bourreille
    Xavier Roblin
    Laurent Peyrin-Biroulet
    Stephanie Viennot
    Mathurin Flamant
    David Laharie
    Bénédicte Caron
    Marie Dewitte
    Laurent Siproudhis
    Mathurin Fumery
    Guillaume Bouguen
    BMC Gastroenterology, 23
  • [30] Letter: effectiveness of ustekinumab or vedolizumab in Crohn's disease following anti-TNF failure-getting closer to the truth?
    Liu, Kecheng
    Cai, Fuqing
    Huang, Jiean
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2020, 52 (07) : 1253 - 1254
12345